SCHEMBL260716

SCHEMBL260716

CC1(C)OC2C(C(=O)O)OC(n3cnc4c(O)nc(C#N)nc43)C2O1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 8/20 0.40
ADORA1 P30542 8/20 0.40
PI4KA P42356 1/20 0.40
PI4K2B Q8TCG2 1/20 0.40
PI4K2A Q9BTU6 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
ADORA2A P29274 8/20 0.37
ADORA2B P29275 6/20 0.37
RXFP1 Q9HBX9 1/20 0.37
CTSL P07711 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
HIF1A Q16665 1/20 0.36
AHCY P23526 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
P2RX1 P51575 1/20 0.36
P2RX3 P56373 1/20 0.36
P2RX4 Q99571 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260746 0.90 PI4KA (0.47) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL260607 0.89 ADORA3 (0.55) ADORA3ADORA1ADORA2AADORA2BCTSL
SCHEMBL260418 0.87 ADORA3 (0.51) ADORA3ADORA1ADORA2AADORA2B
SCHEMBL260760 0.83 PI4KA (0.59) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL260636 0.82 ADORA3 (0.39) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL260577 0.82 PI4KA (0.47) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL12935989 0.80 ADORA3 (0.55) ADORA3ADORA1ADORA2AADORA2B
SCHEMBL260775 0.79 ADORA3 (0.51) ADORA3ADORA1ADORA2AADORA2B
SCHEMBL22757370 0.79 PI4KA (0.44) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL280519 0.79 ADORA2A (0.47) ADORA3ADORA1PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133880-B2 Purine derivatives and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2012-03-13 US disclosed
US-8133880-B2 Purine derivatives and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2012-03-13 US disclosed
US-20110059915-A1 PURINE DERIVATIVES AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2011-03-10 US disclosed
US-20110059915-A1 PURINE DERIVATIVES AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2011-03-10 US disclosed
US-7863253-B2 Purine Derivatives and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2011-01-04 US disclosed
US-20070238694-A1 Purine compounds and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2007-10-11 US disclosed
US-20070238694-A1 Purine compounds and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238694-A1 Purine compounds and methods of use thereof PNP, ADORA2A, P2RY1 ADORA3 28/4885ADORA1 9/4885PI4KA 3135/4885
US-20110059915-A1 PURINE DERIVATIVES AND METHODS OF USE THEREOF PNP, NUDT1, HPRT1 ADORA3 26/4885ADORA1 22/4885PI4KA 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.